Cytoreductive Therapy For Patients With Pv

Selecting Cytoreductive Therapy for Patients with PV or ET

Targeted Oncology

Indication for cytoreductive therapy in ET and PV: Do we have it right?

Current therapy options and clinical outcomes analysis in patients with PV

Use of Cytoreductive Therapy in Patients with Low Risk Polycythemia Vera

International Academy for Clinical Hematology IACH

Cytoreductive Therapy in Polycythemia Vera

The management of polycythemia vera with cytoreductive drug therapy

VJHemOnc – Video Journal of Hematology & HemOnc

Treatment goals in Essential Thrombocythemia and Polycythemia vera

Initiating Cytoreductive Therapy in Polycythemia Vera

Targeted Oncology

Long-acting interferon: What is the difference?

Prognostication and initiation of therapy in Polycythemia vera: Do we have it right?

Assessment of novel treatment options for patients with PV

Treatment for PV: Moving Beyond Hydroxyurea

Targeted Oncology

Available Treatment Options for Patients With PV

Targeted Oncology

Srdan Verstovsek, MD, PhD: The Risk of Thrombosis in PV

How Do You Treat PV Patients That Fail Hydroxyurea (HU)?

Development of long-acting interferon as new therapy for PV and ET

How I Treat Polycythemia Vera - Alessandro Vannucchi, MD

American Society of Hematology

Evolution of the Assessment of Clinical Benefit in Polycythemia Vera

Risk-adapted treatment of ET & PV

VJHemOnc – Video Journal of Hematology & HemOnc

New guidelines for the treatment and management of polycythemia vera

VJHemOnc – Video Journal of Hematology & HemOnc